RT Journal Article
SR Electronic
T1 Radiosurgery or Fractionated Stereotactic Radiotherapy plus Whole-brain Radioherapy in Brain Oligometastases: A Long-term Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3055
OP 3059
VO 35
IS 5
A1 MARIO BALDUCCI
A1 ROSA AUTORINO
A1 SILVIA CHIESA
A1 GIANCARLO MATTIUCCI
A1 ANGELO POMPUCCI
A1 LUIGI AZARIO
A1 GIUSEPPE ROBERTO D'AGOSTINO
A1 MILENA FERRO
A1 ALBA FIORENTINO
A1 SERGIO FERSINO
A1 CIRO MAZZARELLA
A1 CESARE COLOSIMO
A1 VINCENZO FRASCINO
A1 CARMELO ANILE
A1 VINCENZO VALENTINI
YR 2015
UL http://ar.iiarjournals.org/content/35/5/3055.abstract
AB Aim: To analyze the outcome of patients with brain oligometastases treated by radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) after whole-brain radiotherapy (WBRT). Patients and Methods: Overall survival (OS) and local control (LC) were evaluated in patients (patients) with 1-2 brain metastases. Results: Forty-seven patients were selected. They were submitted to WBRT (median dose=3,750 cGy) followed by SRS (17 patients; median dose=1,500 cGy) or FSRT (30 patients; median dose=2,000 cGy). Median follow-up was 102 months (range=17-151); the median survival was 22 months for the SRS group and 16 months for the FSRT group. One-year and 5-year survival was 56% and 16%, respectively, in SRT and 62.1% and 3%, respectively, in FSRT. Neither treatment proved to significantly impact OS (p=0.4). The 1-year LC rates were 80% and 61.1% in the two groups, respectively (p=0.15). Conclusion: SRS or FSRT after WBRT could offer the same outcomes in patients with brain oligometasteses. Further investigation is warranted to confirm these data and define the optimal stereotactic modality.